Mooney Patrick H. 4

What Happened

• Patrick H. Mooney, CEO of SpyGlass Pharma, received a grant/award covering 300,000 shares (reported as a derivative award) on Feb 5, 2026. The Form 4 lists a transaction price of $0.00 (recorded as an award), so no cash was paid on the reported grant.

Key Details

• Transaction date: February 5, 2026; Form 4 filed February 9, 2026.
• Reported amount: 300,000 shares (derivative award); transaction price shown as $0.00 (total value reported $0 on Form 4).
• Vesting: 25% of the shares vest on the one-year anniversary of the Vesting Commencement Date (Feb 5, 2027), then 1/48th of the total shares vest each month thereafter — effectively a four-year vesting schedule, subject to continued service per the 2026 Equity Incentive Plan (see footnote).
• Shares owned after the transaction: not specified in the filing.
• No indication in this filing of an exercise, sale, tax withholding, or 10b5-1 plan.

Context

• This is an equity award (derivative grant) tied to continued service; it is not an open-market purchase or sale and does not by itself indicate trading intent. The vesting schedule (one-year cliff then monthly vesting over three additional years) is a common executive compensation structure.